Search results for " administration"

showing 10 items of 4299 documents

Time Course of 5-HT2A Receptor Occupancy in the Human Brain after a Single Oral Dose of the Putative Antipsychotic Drug MDL 100,907 Measured by Posit…

1997

MDL 100,907 is a potent and selective antagonist of 5-HT2A serotonin receptors. Animals studies suggest that MDL 100,907 may behave as an atypical antipsychotic drug. Positron emission tomograph (PET) using [11C]NMSP as the radiotracer was used to define the time course of 5-HT2 receptor occupancy in the human frontal cerebral cortex after a single oral dose of MDL 100,907 (10 or 20 mg) in nine healthy subjects. After the baseline scan each subject was studied three times post dosing at various time points. 5-HT2 occupancies were in the range of 70 and 90% after each dose. While the occupancy remains in this range over 24 hours after 20 mg MDL 100,907, it decreases by about 20% at 24 hours …

AdultMaleTime Factorsmedicine.drug_classAtypical antipsychoticPharmacologyPiperidinesOral administrationmedicineHumansReceptor Serotonin 5-HT2ACarbon RadioisotopesPositron emissionDosing5-HT receptorPharmacologymedicine.diagnostic_testbusiness.industry5-HT2 receptorBrainHuman brainFluorobenzenesPsychiatry and Mental healthmedicine.anatomical_structureSpiperonePositron emission tomographyReceptors SerotoninFemaleSerotonin AntagonistsbusinessAntipsychotic AgentsTomography Emission-ComputedNeuropsychopharmacology
researchProduct

Transcranial Doppler diagnosis of cerebral vasospasm following subarachnoid haemorrhage: correlation and analysis of results in relation to the age o…

1994

A retrospective analysis was undertaken to determine whether cerebral vasospasm following subarachnoid haemorrhage (SAH) correlates with the age of patients. For at least 3 weeks after bleeding 80 subjects underwent very close follow-up with clinical examination and transcranial Doppler records of the blood velocities within the basal cerebral arteries. Firstly a correlation between measured maximal mean blood flow velocities and age was made. Secondly, according to their age and the maximum of recorded mean velocities (v), the patients were divided into groups as follows: age 55 years or less, age more than 55 years; and maximum velocity v190 cm/s, 90 cm/sv2120 cm/s, 120 cm/sv3160 cm/s, v4…

AdultMaleUltrasonography Doppler TranscranialCerebral arteriesAneurysm RupturedDrug Administration ScheduleCerebral vasospasmMedicineHumanscardiovascular diseasesNeuroradiologyAgedRetrospective StudiesDose-Response Relationship Drugbusiness.industryVascular diseaseAge FactorsVasospasmIntracranial AneurysmLaser Doppler velocimetryMiddle AgedSubarachnoid Hemorrhagemedicine.diseasenervous system diseasesTranscranial Dopplermedicine.anatomical_structureIschemic Attack TransientAnesthesiaCerebrovascular CirculationSurgeryFemaleNimodipineNeurology (clinical)businessBlood Flow VelocityArteryFollow-Up StudiesActa neurochirurgica
researchProduct

The functioning of central categories Middle Level and Sometimes in graded response scales: Does the label matter?

2007

The present study evaluates the extent to which central categories explicitly labeled as being in the middle of the other response categories, specifically Middle Level and Sometimes, function as expected according to the integer scoring system. The assumptions are tested by means of Bock's Nominal Model in two 5-response scales. Results show that the assumption of the ordering of the response categories is met for all the items. The ordering of thresholds is satisfied for all but one item with the central category Middle Level . Results are compared with those obtained when middle categories are not explicitly labeled as being in the middle of the other response categories, as in the case …

AdultMaleWorkAdministrative PersonnelModels TheoreticalChoice BehaviorJob SatisfactionSampling StudiesTests psicològicsResearch DesignSpainSurveys and QuestionnairesTerminology as TopicQuality of LifeHumansFemalePublic HealthPublic Health Administration
researchProduct

Addition of a second opioid may improve opioid response in cancer pain: preliminary data

2004

Recent experimental data suggest a possible use of an opioid combination to improve analgesia. In cancer patients, a rapid opioid escalation due to either worsening of the pain condition or the development of tolerance is a critical phase, as this condition is associated with a negative prognosis. The aim of this study was to assess the effects of adding a second opioid at low doses in patients with a poor analgesic benefit after dose escalation. Fourteen patients receiving strong opioids who had increased their dosage more than 100% in the last week unsuccessfully were randomly chosen to add a second opioid to the first using an initial equivalent dosage of 20% of the previous therapy. The…

AdultMalecancer painMaximum Tolerated DosePain medicineAnalgesicPainRisk AssessmentSeverity of Illness IndexDrug Administration ScheduleStatistics Nonparametriclaw.inventionPharmacotherapyRandomized controlled triallawNeoplasmsMedicineHumansTerminally IllProspective StudiesKarnofsky Performance StatusAdverse effectAgedPain MeasurementProbabilityTerminal CareDose-Response Relationship DrugMorphinebusiness.industryMiddle AgedClinical trialAnalgesics OpioidFentanylTreatment OutcomeOncologyOpioidopioid responseAnesthesiaopioid treatmentDrug Therapy CombinationFemaleCancer painbusinessmedicine.drug
researchProduct

Plasma levels of benperidol, prolactin, and homovanillic acid after intravenous versus two different kinds of oral application of the neuroleptic in …

2009

Plasma levels of prolactin (PRL) and the butyrophenone neuroleptic benperidol (BPD) were closely followed 0 to 48 h after acute application of 6 mg BPD as intravenous injection, orally as liquid, and orally as tablets in 12 schizophrenic patients using a partially randomized cross over design. Drug concentrations showed application specific pharmacokinetic behavior with complete elimination within 48 h. All three applications led to a biphasic PRL response with pronounced initial plasma PRL peaks returning to baseline levels within 48 h. The results suggest that after acute neuroleptic challenge BPD plasma levels as low as 2-3 ng/ml can be sufficient for complete depletion of pituitary PRL …

AdultMaleendocrine systemmedicine.medical_specialtyEndocrinology Diabetes and MetabolismAdministration OralPharmacologyBenperidolchemistry.chemical_compoundEndocrinologyPharmacokineticsOral administrationInternal medicinemental disordersInternal MedicinemedicineHumansCross-Over Studiesbusiness.industryBenperidolHomovanillic acidDopaminergicAntagonistHomovanillic AcidGeneral MedicineProlactinProlactinEndocrinologychemistryInjections IntravenousSchizophreniaFemalebusinesshormones hormone substitutes and hormone antagonistsmedicine.drugHormoneExperimental and Clinical Endocrinology & Diabetes
researchProduct

Can Graduated Compressive Stockings Reduce Muscle Activity During Running?

2017

Purpose: Graduated compressive stockings (GCS) have been suggested to influence performance by reducing muscle oscillations and improving muscle function and efficiency. However, no study to date has analyzed the influence of GCS on muscle activity during running. The objective of the study was to analyze the influence of GCS on the perception of comfort and muscle activation of the main muscles of the lower leg during running. Method: Thirty-six participants ran on a treadmill with (GCS) or without (control) GCS. The running tests consisted of a 10-min warm-up followed by a 20-min intense run at 75% of the athlete’s maximal aerobic speed. Surface electromyography of the tibialis anterior, …

AdultMaleendocrine systemmedicine.medical_specialtyPhysical Therapy Sports Therapy and RehabilitationElectromyographyRunning03 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitationhealth services administrationpolycyclic compoundsPeroneus longusmedicineEducación Física y DeportivaHumansOrthopedics and Sports MedicineStatistical analysisTreadmillMuscle activityMuscle SkeletalFatigueLegmedicine.diagnostic_testbusiness.industryElectromyographyCompressionMuscle activation030229 sport sciencesGeneral MedicineNephrologyMuscle FatiguePhysical therapyFemalePerceptionsense organsbusinesshormones hormone substitutes and hormone antagonists030217 neurology & neurosurgeryGastrocnemius medialisStockings CompressionResearch quarterly for exercise and sport
researchProduct

Gonadotropin and Testosterone Secretion in Normal Human Males After Stimulation With Gonadotropin-Releasing Hormone (Gnrh) or Potent Gnrh Analogs Usi…

1978

Gonadotropin-releasing hormone (GnRH) and some potent long-acting GnRH analogs, applied by different routes of administration, were tested in six healthy human males. The effects on gonadotropin secretion were compared with the one after intravenous (i.v.) bolus injection of 25 microgram of GnRH. The net increase of luteinizing hormone (deltaLH) in serum produced by 25 microgram of GnRH i.v. was matched by subcutaneous (s.c.) injection of 100 microgram of GnRH, dissolved in 20% gelatin or without gelatin; 5 microgram of D-Ser (TBU)6-des-Gly10-GnRH-ethylamide i.v.; 5 microgram of D-Leu6-des-Gly10-GnRH-ethylamide i.v.; and 50 microgram of D-Trp6-des Gly10-GnRH-ethylamide given pernasally (p.n…

AdultMaleendocrine systemmedicine.medical_specialtyTime Factorsmedicine.drug_classMicrogramStimulationGonadotropin-releasing hormoneGonadotropin-Releasing HormoneInternal medicinemedicineHumansInfusions ParenteralTestosteroneAdministration IntranasalChemistryObstetrics and GynecologyLuteinizing HormoneHormonesGonadotropin secretionEndocrinologyReproductive MedicineInjections IntravenousNasal administrationFollicle Stimulating HormoneGonadotropinLuteinizing hormonePituitary Hormone-Releasing Hormoneshormones hormone substitutes and hormone antagonistsHormoneFertility and Sterility
researchProduct

Intranasal fentanyl versus fentanyl pectin nasal spray for the management of breakthrough cancer pain in doses proportional to basal opioid regimen.

2014

Abstract The aim of this randomized, crossover, comparison study was to assess the analgesic and adverse effects of 2 nasal preparations, intranasal fentanyl (INFS) and fentanyl pectin nasal spray (FPNS), for breakthrough pain, given in doses proportional to opioid basal regimen. Each patient randomly received INFS or FPNS in doses proportional to opioid dosages used for background analgesia for 2 pairs of episodes. For each episode of breakthrough pain, pain intensity and adverse effects intensity were recorded just before starting the INFS or FPNS (T0) and 5 minutes (T5), 10 minutes (T10), and 20 minutes (T20) after the administration of the nasal drugs. Sixty-nine patients were studied. …

AdultMalefentanyl pectin nasal spraymedicine.medical_treatmentAnalgesicSettore MED/42 - Igiene Generale E ApplicataFentanylrapid-onset opioidsNeoplasmsparasitic diseasesMedicineHumansCancer painAdverse effectAgedPain MeasurementAged 80 and overDose-Response Relationship Drugbusiness.industryBreakthrough Painintranasal fentanylNasal SpraysMiddle AgedCancer pain; breakthrough pain; fentanyl pectin nasal spray; intranasal fentanyl; rapid-onset opioidsAnalgesics OpioidFentanylRegimenAnesthesiology and Pain MedicineCross-Sectional StudiesNeurologyOpioidNasal sprayAnesthesiaPectinsNasal administrationFemaleNeurology (clinical)businessCancer painmedicine.drugThe journal of pain
researchProduct

Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a …

2007

Abstract Background To compare the efficacy and safety of three different chemotherapy doublets in the treatment of advanced pancreatic cancer (PC). Patients and methods At total of 190 patients were randomly assigned to receive capecitabine 1000 mg/m2 twice daily on days 1–14 plus oxaliplatin 130 mg/m2 on day 1 (CapOx), capecitabine 825 mg/m2 twice daily on days 1–14 plus gemcitabine 1000 mg/m2 on days 1 and 8 (CapGem) or gemcitabine 1000 mg/m2 on days 1 and 8 plus oxaliplatin 130 mg/m2 on day 8 (mGemOx). Treatment cycles were repeated every three weeks. The primary end point was progression-free survival (PFS) rate at 3 months; secondary end points included objective response rate, carboh…

AdultMalemedicine.medical_specialtyAdolescentMaximum Tolerated DoseOrganoplatinum CompoundsPhases of clinical researchKaplan-Meier EstimateDeoxycytidineRisk AssessmentGastroenterologyDisease-Free SurvivalDrug Administration ScheduleCapecitabineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansSingle-Blind MethodProgression-free survivalInfusions IntravenousCapecitabineAgedNeoplasm StagingProbabilityDose-Response Relationship Drugbusiness.industryCAPOX RegimenHematologyMiddle AgedImmunohistochemistrySurvival AnalysisGemcitabineGemcitabineOxaliplatinSurgeryOxaliplatinPancreatic NeoplasmsRegimenTreatment OutcomeOncologyTolerabilityFemaleFluorouracilbusinessFollow-Up Studiesmedicine.drugAnnals of Oncology
researchProduct

Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depressi…

2003

OBJECTIVE Current clinical knowledge holds that antidepressants have a delayed onset of efficacy. However, the delayed onset hypothesis has been questioned recently by survival analytical approaches. We aimed to test whether early improvement under antidepressant treatment is a clinically useful predictor of later stable response and remission. METHOD We analyzed data from a randomized double-blind controlled trial with mirtazapine and paroxetine in patients with major depression (DSM-IV). Improvement was defined as a 17-item Hamilton Rating Scale for Depression (HAM-D-17) score reduction of > or = 20%. Stable response was defined as > or = 50% HAM-D-17 score reduction at week 4 and week 6,…

AdultMalemedicine.medical_specialtyAdolescentMirtazapineMirtazapineMianserinAntidepressive Agents TricyclicDrug Administration Schedulelaw.inventionRandomized controlled trialDouble-Blind MethodlawInternal medicinemedicineAmbulatory CareHumansPsychiatrySurvival analysisDepression (differential diagnoses)AgedPsychiatric Status Rating ScalesDepressive DisorderHamilton Rating Scale for DepressionMiddle AgedPrognosisParoxetineSurvival AnalysisClinical trialPsychiatry and Mental healthParoxetineTreatment OutcomeAntidepressantDrug Therapy CombinationFemalePsychologySelective Serotonin Reuptake Inhibitorsmedicine.drug
researchProduct